Member Info for AquaeSulis01

Bel, if it becomes the key ingredient Croda believe it to be then 12000 Customers wanting the lysate in their products will keep the production line pretty busy I would say

One further thought belgrano, if you were in charge of skinbiotix production and you felt that a very infrequent run would satisfy customer demand wouldn't you just have stopped at 600 litres run continuously rather than bother with a 20000 litre scale-up?

Gents you appear to be going down a bit of a rabbit hole here. elrico you have stated that the £5m dedicated investment is nothing to Croda so easy enough to drop and write off if they do wish, whilst belgrano you recognise that in some cases where usage warrants it there are dedicated full time production lines. Worth remembering this venture with Croda and Sederma has been going on for over 3 years and two scale ups so will most certainly will proceed, and also the words "essential ingredient" from Sederma when the agreement was signed if proving true will determine the frequency of future production runs. "Arnaud Fournial, Managing Director of Sederma, said:

"The SkinBiotix™ technology has a solid scientific foundation which attracted us in the first place. We believe the technology has the potential to become an essential and significant component of cosmetic products within the rapidly emerging skin microbiome market. We look forward to a fully collaborative partnership with the SkinBioTherapeutics team and to seeing SkinBiotix™ being embraced by our global partners as a key ingredient across a variety of products to protect and rejuvenate skin."

Toyin if the acquisition lands there will be an additional fundraise. None of the £2.5M minus expenses is for the acquisition itself other than to show sufficient funds exist to be a going concern over the next 12 months. From the placing RNS "The Company is in ongoing discussions to acquire a private company that provides a variety of branded topical products for common dermatological conditions such as psoriasis and eczema to NHS hospitals, dispensing practices and retail pharmacies. The proposed target is profitable and the Company sees a number of synergies to improve this. However, there is no certainty of timing or execution as the Company would need to agree additional funding using debt and/or equity and any acquisition would be conditional on satisfactory diligence"

Reiterates 2023 for sweetbiotix and any uptick in prebiotic sales in the interim on the back of the new territories and move to selling end products rather than ingredients a bonus.

elrico you are reading too many posts too quickly, have a break and come back refreshed on the New Year. It is obvious Friedman is talking about SOH not you

bel, what are you on about when you say we had no-one doing the Accounts for a good part of the year? Doug Quinn was paid right to the end of June if you check the remuneration in the audited accounts and Manprit was there for a handover period as there is an expense for him to the end of June

Cheers mol, and happy xmas and New Year to you and all investors

Sorry for the near duplicate, the computer froze and I thought the initial reply had been lost

Friedman, the company comms are awful (we still haven't had the Q&As answered from the Investor Meet over a month ago) so outside current holders and a few ex stale bull holders doubtful too many know about the prospects here. Throw in the impromptu fund raise where a large number of the 3M shares issued have probably been dumped back on the market and no wonder the sp has collapsed. Finances in H2 will include re-orders from the likes of H&B and the Australian partner, new territories including India's Apollo Hospitals for Go-Figure products rather than ingredient royalties, and the six digit milestone payment from the US Partner. Any positive news following the commercial meeting between skin and Croda next month will see a re-rate in the value of Opti's 20% holding and finally when, not if, the sweetbiotix news does drop the herd will arrive in their droves but they will not be getting in at anything like today's share price. This company with its holdings in both Skinbio and Probiotic Health along with the cash now held is not going bust anytime soon and there are any number of AIM companies with a market cap far greater than Opti's £11M that are far riskier and more likely to go bust than ever turn a profit.

Friedman easy to understand why sentiment is rock bottom, communication from the company is awful with Investor Meets questions still not addressed over a month later, H1 finances for prebiotics fallen off a cliff edge, the value of the skinbiotherapeutics holding fallen to a point where it would be folly to sell them and hence the impromptu fundraise where the likelihood is that a substantial number of the 3M shares have not gone into sticky hands and hence been dumped on the market. So assuming we are just about at rock bottom what are the positives? Prebiotics sales will have risen significantly in H2 with reduced bulk orders from the likes of H&B and the Australian Partner now received, there will be sales from the new territories in particular Go-Figure products rather than the slimbiome ingredient in Apollo Hospitals in India. The 6 figure milestone payment from the US Partner will be paid this month and it is what you as an investor believes about the prospect of sweetbiotics products launching this year that matters not how the market in general currently behaves. Finally, should positive news following the skinbio commercial meeting with Croda in Jan 2023 cause a re-rate in skins share value, we may even reach the ludicrous situation where Opti's holding exceeds its current now £M market cap.

Fried, as previously stated, something has changed regarding sweetbiotix; the US Partner for the "Monk Fruit" based sweetbiotix products has completed the optimisation of their scale-up process and SOH has provided a 2023 launch date of products from that source and there is now a second named partner for the stevenol based sweetbiotix products that is pushing Opti for progress rather than the reverse

SOH's refusal to compromise margins and get the product onto major supermarket shelves in the UK has certainly cost the company dear especially how that niche partners like THG whose insurer will no longer guarantee suppliers get paid, and H&B struggle to sell discretionary products (Just received my latest batch of slimexpert porridge with bbd of 31/01/23!).
Only consolation is that sales of the probiotix side of the business now with Probiotix Health have held up pretty well, Skinbiotherapeutics have raised enough to keep the lights on for a year when royalties for skinbiotix via Croda should kick in preserving the value of Opti's holding in that company, and the second generation products finally look to be nearing a launch. So with the Market Cap of just £12M covered by the value of its holdings in Probiotix Health and Skinbio, it really is just a case of sitting and suffering until sweetbiotix hits the streets. On that note, it would be good if SOH made samples of the US Partner "sugar substitute in coffee" available for shareholders to try to help remove the bitter taste of the current share price.

https://www.proactiveinvestors.co.uk/companies/news/1001511/skinbiotherapeutics-will-continue-to-be-flexible-enough-to-adapt-to-opportunities-1001511.html

clio, with such a low turnover if pi's bought in significant numbers not too many would acquire the shares at less than or at the offer price so that is why I didn't add it as a point 3

Legal, we have visible sulphides at two of the three completed holes so far; DH1-6B at 600M down and for DDH1-3A nickel sulphides visible at a depth of 327M down and at more significant levels between 348-354M down. As regards thickness levels, the Bushveld Complex always held up as one of the best mines in the world is renowned for the length of its resource not the thickness of the seam and I think people forget that the size of the Molopo Farms complex, the current in progress drill hole DDH2-3A sits in a target area T2-3 that on its own is stretches over 12 kilometres.

I'll add my thanks to elrico for carrying out the interview whilst feeling very much under the weather. Bel, I don't believe that there would have been any further uptick in the Rex Retail offer take-up, many pi's are already maxed out with their holdings here in relation to the rest of their portfolios and will be waiting to see two things in Jan 2023:
1) Have the shares taken up by ii's genuinely gone to "sticky hands" and
2) Confirmation from Croda to SA that royalty revenue is now being generated in accordance with their plan which remains on target.
Another grey cloud on the horizon is ex Director Doug Quinn's lock-in period expires Jan 2023 although I don't believe he will consider selling at anything like the current share price.

All have a Great Xmas and hope we all have a Happy and Prosperous New Year

elrico with regards your YouTube link bear in mind this warning in the placement RNS "IMPORTANCE OF THE VOTE AND DIRECTORS' RECOMMENDATION



Shareholders should be aware that, should Shareholder approval not be obtained at the General Meeting, neither the Placing nor the Retail Offer will proceed and the Company would not receive the funds relating to the Placing or the Retail Offer which would limit the amount of working capital available to it. The Company would need to consider the options available to it in terms of alternative sources of funding. It may be that such sources would not be available or not available on favourable terms. Accordingly, if alternative sources of funding could not be secured, the Company expects that it would not have sufficient cash for its current level of activities beyond early in the second quarter of calendar year 2023.

So the fundraise is very much about working capital as well t o keep the lights on despite Stuart dismissing it.

Bel the amount the directors are subscribing for are shown in the fundraise RNS

Croda not cross